Skip to Content
Morningstar

Adicet Bio Inc Ordinary Shares ACET

Morningstar Rating
Unlock
Stock XNAS Rating as of
$2.03 −0.25 (10.79%)
View Full Chart
As of Delayed Price Pre-Open: $2.03 0.00
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
ACET is trading at a 71% discount.
Price
$2.02
Fair Value
$7.37
Uncertainty
Extreme
1-Star Price
$219.79
5-Star Price
$8.22
Economic Moat
Jbpkg
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACET is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$2.27
Day Range
$2.01–2.29
52-Week Range
$1.10–7.50
Bid/Ask
$2.00 / $2.06
Market Cap
$166.36 Mil
Volume/Avg
204 / 1.3 Mil

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
143
Website
https://www.adicetbio.com

Comparables

Valuation

View More
Metric
ACET
ANAB
RCUS
Price/Earnings (Normalized)
 ———
Price/Book Value
 0.515.992.43
Price/Sales
 —31.129.39
Price/Cash Flow
 ———
Price/Earnings
ACET
ANAB
RCUS

Financial Strength

Metric
ACET
ANAB
RCUS
Quick Ratio
 8.2810.624.35
Current Ratio
 8.4110.874.52
Interest Coverage
 −6,104.44−9.09−170.00
Quick Ratio
ACET
ANAB
RCUS

Profitability

Metric
ACET
ANAB
RCUS
Return on Assets (Normalized)
 −38.02%−23.50%−20.42%
Return on Equity (Normalized)
 −44.28%−75.96%−44.44%
Return on Invested Capital (Normalized)
 −44.36%−68.56%−49.53%
Return on Assets
ACET
ANAB
RCUS
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRBwsbdhhtzBmv$550.4 Bil
VRTX
Vertex Pharmaceuticals IncPpdfkjmnzMpkrng$101.7 Bil
REGN
Regeneron Pharmaceuticals IncSjmwbwwjFxrrq$98.1 Bil
MRNA
Moderna IncVdgzdsgqSdwzl$39.1 Bil
ARGX
argenx SE ADRFqvtyjdwzWcb$21.7 Bil
BNTX
BioNTech SE ADRHctcgqjsLsww$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncBscrjmxdXmkqbp$18.4 Bil
BMRN
Biomarin Pharmaceutical IncTrvpgrywqHjwyy$17.1 Bil
RPRX
Royalty Pharma PLC Class AFgjvjjyhmQgtnnh$12.5 Bil
INCY
Incyte CorpXxgwlbsyHgprdd$11.9 Bil

Sponsor Center